The UAE has officially authorized the use of the oral version of Wegovy (semaglutide), making it the second nation in the world to approve this once-daily medication. Designed for adults struggling with obesity or weight-related health issues, this GLP-1 receptor agonist is intended to be used as part of a comprehensive lifestyle plan that includes a calorie-controlled diet and regular exercise. Beyond its primary role in weight management, clinical studies have highlighted the drug’s secondary benefit in lowering the risk of severe cardiovascular complications, such as heart attacks, strokes, and cardiovascular-related deaths in high-risk patients.

Dr. Fatma Al Kaabi, Director General of the Emirates Drug Establishment, emphasized that this approval underscores the UAE's dedication to integrating cutting-edge pharmaceutical innovations into its healthcare system. By providing earlier access to proven treatments, the country aims to proactively tackle obesity and its associated chronic conditions. Novo Nordisk’s regional management echoed this sentiment, noting that the oral formulation offers a convenient and effective option for patients, further strengthening the medical community's ability to provide high-quality, long-term care for those in need.